|Bid||170.95 x 800|
|Ask||182.58 x 800|
|Day's Range||173.01 - 177.92|
|52 Week Range||76.85 - 177.92|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||295.72|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Repligen crossed an early entry above 157.56. It wasn't just biotechs participating today, many medical related stocks were also strong.